Interfering with the PD-1/PD-L1 immune checkpoint showed superior clinical benefit compared to CTLA-4 blockade, which might be due to the less restricted expression pattern of PD-1 and its ligands, particularly PD-L1 in tumor cells. Here, CTLA4 is linked to neoplasm.